90 related articles for article (PubMed ID: 28009971)
1. Dacomitinib, a new pan-EGFR inhibitor, is effective in killing ovarian cancer cells.
Xu L; Wu H; Jiang C; Wang H; Gao B; Yan S; Qi Y; Zhou S
Discov Med; 2016 Nov; 22(122):297-309. PubMed ID: 28009971
[TBL] [Abstract][Full Text] [Related]
2. Dacomitinib, a pan-inhibitor of ErbB receptors, suppresses growth and invasive capacity of chemoresistant ovarian carcinoma cells.
Momeny M; Zarrinrad G; Moghaddaskho F; Poursheikhani A; Sankanian G; Zaghal A; Mirshahvaladi S; Esmaeili F; Eyvani H; Barghi F; Sabourinejad Z; Alishahi Z; Yousefi H; Ghasemi R; Dardaei L; Bashash D; Chahardouli B; Dehpour AR; Tavakkoly-Bazzaz J; Alimoghaddam K; Ghavamzadeh A; Ghaffari SH
Sci Rep; 2017 Jun; 7(1):4204. PubMed ID: 28646172
[TBL] [Abstract][Full Text] [Related]
3. The pan-inhibitor of Aurora kinases danusertib induces apoptosis and autophagy and suppresses epithelial-to-mesenchymal transition in human breast cancer cells.
Li JP; Yang YX; Liu QL; Zhou ZW; Pan ST; He ZX; Zhang X; Yang T; Pan SY; Duan W; He SM; Chen XW; Qiu JX; Zhou SF
Drug Des Devel Ther; 2015; 9():1027-62. PubMed ID: 25733818
[TBL] [Abstract][Full Text] [Related]
4. Pan-EGFR Inhibitor Dacomitinib Resensitizes Paclitaxel and Induces Apoptosis via Elevating Intracellular ROS Levels in Ovarian Cancer SKOV3-TR Cells.
Lim YJ; Kim HS; Bae S; So KA; Kim TJ; Lee JH
Molecules; 2024 Jan; 29(1):. PubMed ID: 38202856
[TBL] [Abstract][Full Text] [Related]
5. The ERBB receptor inhibitor dacomitinib suppresses proliferation and invasion of pancreatic ductal adenocarcinoma cells.
Momeny M; Esmaeili F; Hamzehlou S; Yousefi H; Javadikooshesh S; Vahdatirad V; Alishahi Z; Mousavipak SH; Bashash D; Dehpour AR; Tavangar SM; Tavakkoly-Bazzaz J; Haddad P; Kordbacheh F; Alimoghaddam K; Ghavamzadeh A; Ghaffari SH
Cell Oncol (Dordr); 2019 Aug; 42(4):491-504. PubMed ID: 31025257
[TBL] [Abstract][Full Text] [Related]
6. Antitumour effects and mechanisms of action of the panHER inhibitor, dacomitinib, alone and in combination with the STAT3 inhibitor, S3I-201, in human sarcoma cell lines.
Wang X; Goldstein D; Crowe PJ; Yang JL
Int J Oncol; 2018 Jun; 52(6):2143-2154. PubMed ID: 29620166
[TBL] [Abstract][Full Text] [Related]
7. HCRP1 downregulation promotes hepatocellular carcinoma cell migration and invasion through the induction of EGFR activation and epithelial-mesenchymal transition.
Xu J; Zhang X; Wang H; Ge S; Gao T; Song L; Wang X; Li H; Qin Y; Zhang Z
Biomed Pharmacother; 2017 Apr; 88():421-429. PubMed ID: 28122307
[TBL] [Abstract][Full Text] [Related]
8. Danusertib, a potent pan-Aurora kinase and ABL kinase inhibitor, induces cell cycle arrest and programmed cell death and inhibits epithelial to mesenchymal transition involving the PI3K/Akt/mTOR-mediated signaling pathway in human gastric cancer AGS and NCI-N78 cells.
Yuan CX; Zhou ZW; Yang YX; He ZX; Zhang X; Wang D; Yang T; Pan SY; Chen XW; Zhou SF
Drug Des Devel Ther; 2015; 9():1293-318. PubMed ID: 25767376
[TBL] [Abstract][Full Text] [Related]
9. Metformin sensitizes EGFR-TKI-resistant human lung cancer cells in vitro and in vivo through inhibition of IL-6 signaling and EMT reversal.
Li L; Han R; Xiao H; Lin C; Wang Y; Liu H; Li K; Chen H; Sun F; Yang Z; Jiang J; He Y
Clin Cancer Res; 2014 May; 20(10):2714-26. PubMed ID: 24644001
[TBL] [Abstract][Full Text] [Related]
10. Dacomitinib (PF-00299804), a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor, demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitro.
Zhu L; Lopez S; Bellone S; Black J; Cocco E; Zigras T; Predolini F; Bonazzoli E; Bussi B; Stuhmer Z; Schwab CL; English DP; Ratner E; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Santin AD
Tumour Biol; 2015 Jul; 36(7):5505-13. PubMed ID: 25669172
[TBL] [Abstract][Full Text] [Related]
11. Acquisition of chemoresistance and EMT phenotype is linked with activation of the endothelin A receptor pathway in ovarian carcinoma cells.
Rosanò L; Cianfrocca R; Spinella F; Di Castro V; Nicotra MR; Lucidi A; Ferrandina G; Natali PG; Bagnato A
Clin Cancer Res; 2011 Apr; 17(8):2350-60. PubMed ID: 21220476
[TBL] [Abstract][Full Text] [Related]
12. Dacomitinib in lung cancer: a "lost generation" EGFR tyrosine-kinase inhibitor from a bygone era?
Ou SH; Soo RA
Drug Des Devel Ther; 2015; 9():5641-53. PubMed ID: 26508839
[TBL] [Abstract][Full Text] [Related]
13. Phospho-Akt pathway activation and inhibition depends on N-cadherin or phospho-EGFR expression in invasive human bladder cancer cell lines.
Wallerand H; Cai Y; Wainberg ZA; Garraway I; Lascombe I; Nicolle G; Thiery JP; Bittard H; Radvanyi F; Reiter RR
Urol Oncol; 2010; 28(2):180-8. PubMed ID: 19070520
[TBL] [Abstract][Full Text] [Related]
14. Treatment with cucurbitacin B alone and in combination with gefitinib induces cell cycle inhibition and apoptosis via EGFR and JAK/STAT pathway in human colorectal cancer cell lines.
Yar Saglam AS; Alp E; Elmazoglu Z; Menevse S
Hum Exp Toxicol; 2016 May; 35(5):526-43. PubMed ID: 26183715
[TBL] [Abstract][Full Text] [Related]
15. Dacomitinib compared with placebo in pretreated patients with advanced or metastatic non-small-cell lung cancer (NCIC CTG BR.26): a double-blind, randomised, phase 3 trial.
Ellis PM; Shepherd FA; Millward M; Perrone F; Seymour L; Liu G; Sun S; Cho BC; Morabito A; Leighl NB; Stockler MR; Lee CW; Wierzbicki R; Cohen V; Blais N; Sangha RS; Favaretto AG; Kang JH; Tsao MS; Wilson CF; Goldberg Z; Ding K; Goss GD; Bradbury PA; ; ;
Lancet Oncol; 2014 Nov; 15(12):1379-88. PubMed ID: 25439692
[TBL] [Abstract][Full Text] [Related]
16. Impact of the putative cancer stem cell markers and growth factor receptor expression on the sensitivity of ovarian cancer cells to treatment with various forms of small molecule tyrosine kinase inhibitors and cytotoxic drugs.
Puvanenthiran S; Essapen S; Seddon AM; Modjtahedi H
Int J Oncol; 2016 Nov; 49(5):1825-1838. PubMed ID: 27599579
[TBL] [Abstract][Full Text] [Related]
17. Effects of cigarette smoke extracts on the progression and metastasis of human ovarian cancer cells via regulating epithelial-mesenchymal transition.
Jeon SY; Go RE; Heo JR; Kim CW; Hwang KA; Choi KC
Reprod Toxicol; 2016 Oct; 65():1-10. PubMed ID: 27327412
[TBL] [Abstract][Full Text] [Related]
18. Danusertib Induces Apoptosis, Cell Cycle Arrest, and Autophagy but Inhibits Epithelial to Mesenchymal Transition Involving PI3K/Akt/mTOR Signaling Pathway in Human Ovarian Cancer Cells.
Zi D; Zhou ZW; Yang YJ; Huang L; Zhou ZL; He SM; He ZX; Zhou SF
Int J Mol Sci; 2015 Nov; 16(11):27228-51. PubMed ID: 26580601
[TBL] [Abstract][Full Text] [Related]
19. HPIP promotes epithelial-mesenchymal transition and cisplatin resistance in ovarian cancer cells through PI3K/AKT pathway activation.
Bugide S; Gonugunta VK; Penugurti V; Malisetty VL; Vadlamudi RK; Manavathi B
Cell Oncol (Dordr); 2017 Apr; 40(2):133-144. PubMed ID: 28039608
[TBL] [Abstract][Full Text] [Related]
20. Response to epidermal growth factor receptor inhibitors in non-small cell lung cancer cells: limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or Akt kinase pathways.
Janmaat ML; Kruyt FA; Rodriguez JA; Giaccone G
Clin Cancer Res; 2003 Jun; 9(6):2316-26. PubMed ID: 12796401
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
